Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AKT Gene Mutation”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Early research (Phase 1)Active Not RecruitingNCT07038369
What this trial is testing

ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Who this might be right for
Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more
Atavistik Bio, Inc 134
Testing effectiveness (Phase 2)Looking for participantsNCT02523014
What this trial is testing

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Who this might be right for
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology 124
Early research (Phase 1)Ended earlyNCT04770246
What this trial is testing

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsAdvanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
Taiho Oncology, Inc. 17
Testing effectiveness (Phase 2)Study completedNCT01277757
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast Cancer+1 more
National Cancer Institute (NCI) 30
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Looking for participantsNCT05455619
What this trial is testing

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
SynDevRx, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT01333475
What this trial is testing

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Who this might be right for
Colorectal Neoplasms
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Study completedNCT01625286
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

Who this might be right for
Advanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer
AstraZeneca 148
Not applicableEnded earlyNCT05571670
What this trial is testing

Bile Acids in Acute Insulin Resistance

Who this might be right for
PI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more
Columbia University 3
Early research (Phase 1)Ended earlyNCT04586270
What this trial is testing

TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Who this might be right for
Advanced or Metastatic Solid Tumors
Taiho Oncology, Inc. 47
Early research (Phase 1)Active Not RecruitingNCT06533059
What this trial is testing

Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Who this might be right for
CancerBreast CancerEndometrial Cancer+2 more
Alterome Therapeutics, Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Testing effectiveness (Phase 2)Study completedNCT01307631
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+2 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Next Page